RT Journal Article
SR Electronic
T1 Increased disparity in routine infant vaccination during COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.30.22277115
DO 10.1101/2022.06.30.22277115
A1 Righolt, Christiaan H.
A1 Pabla, Gupreet
A1 Mahmud, Salaheddin M.
YR 2022
UL http://medrxiv.org/content/early/2022/07/02/2022.06.30.22277115.abstract
AB Background COVID-19 restrictions and its impact on healthcare resources have reduced routine infant vaccine uptake, although some report that this effect was short-lived. These prior studies mostly described entire populations, but disparities in uptake may have changed during the pandemic due to differential access to healthcare.Objectives We aimed to examine disparities in the reduction in routine infant vaccine uptake during the COVID-19 pandemic in Manitoba, Canada.Methods We assessed vaccine uptake for routine infant vaccines for a pre-pandemic and pandemic subcohort. We assessed how the reduction in vaccine uptake differed by gender, neighborhood income quintile and region of residence. For each evaluation age, we limited the pandemic subcohort to children reaching this milestone age on/before November 30, 2021.Results Vaccine uptake was about 5-10% lower during the pandemic. The groups most vulnerable to COVID-19 saw the largest reductions in vaccine uptake, with an ongoing downward trend throughout the pandemic. Children in the lowest income neighborhoods saw a 17% reduction in diphtheria, tetanus, and acellular pertussis dose 4 uptake at 24 months, 4.4-fold that of high-income neighborhoods, and an 11% reduction in measles, mumps, rubella (MMR) vaccine uptake at 24 months, 5.6-fold that of high-income neighborhoods. The largest reductions were for low-income Northern residents and smallest for high-income Winnipeg residents, e.g. 16-fold larger for MMR at 24 months (79:94 pre-pandemic to 65:93 during the pandemic).Conclusions While privileged children have similar high vaccine uptake as before the pandemic, children in populations hardest hit by COVID-19 continue seeing concerning reductions in routine infant vaccination. It is imperative that infant vaccination rates are increased, especially in communities with lower socioeconomic status, as a failure to do so could lead to persistent rebound epidemics in the most vulnerable populations.Study question How did COVID-19 and its restrictions affect routine infant vaccine uptake?What’s already known We know that vaccine uptake in infants decreased during the pandemic. We do not know whether this affected everyone equally or whether the pandemic worsened existing disparities in vaccine uptake.What this study adds Although vaccine uptake was not affected in wealthy urban neighborhoods, the reduction in uptake was largest, and continued on a downward trend, for groups with the lowest baseline vaccine uptake. Only two-thirds of children, instead of the 4/5th before the pandemic, in the remote, predominantly Indigenous Northern region received a measles vaccine by their second birthday.Competing Interest StatementCHR has received an unrestricted research grant from Pfizer for an unrelated study. GP has no financial relationship to disclose SMM received research funding from Assurex, GSK, Merck, Pfizer, Roche and Sanofi for unrelated studies and is/was a member of advisory boards for GSK, Merck, Sanofi and Seqirus.Funding StatementThis work was funded by the Manitoba Medical Service Foundation (operating grant # 8-2021-03). SMM's work is supported, in part, by funding from the Canada Research Chair Program. The opinions presented in the report do not necessarily reflect those of the funders and the funders had no role in the completion of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Manitoba Research Ethics Board and by the Manitoba Health Health Information Privacy Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this article was derived from administrative health and social data as a secondary use. The data was provided under specific data sharing agreements only for approved use at the Manitoba Centre for Health Policy (MCHP). The original source data is not owned by the researchers or MCHP and as such cannot be provided to a public repository. The original data source and approval for use has been noted in the acknowledgments of the article. Where necessary, source data specific to this article or project may be reviewed at MCHP with the consent of the original data providers, along with the required privacy and ethical review bodies.COVID-19coronavirus disease 2019;DTaPDiphtheria, tetanus, and acellular pertussis;MHManitoba Health;MMRmeasles, mumps, rubella